医学
头孢他啶/阿维巴坦
阿兹屈南
内科学
危险系数
肺炎克雷伯菌
头孢他啶
置信区间
抗生素
比例危险模型
胃肠病学
微生物学
铜绿假单胞菌
大肠杆菌
抗生素耐药性
生物
基因
细菌
遗传学
亚胺培南
生物化学
作者
Marco Falcone,George L. Daikos,Giusy Tiseo,Dimitrios Bassoulis,Cesira Giordano,Valentina Galfo,Alessandro Leonildi,Enrico Tagliaferri,Simona Barnini,Spartaco Sani,Alessio Farcomeni,Lorenzo Ghiadoni,Francesco Menichetti
摘要
Abstract Background In vitro data support the use of combination of aztreonam (ATM) with ceftazidime-avibactam (CAZ-AVI), but clinical studies are lacking. The aim of our study was to compare the outcome of patients with bloodstream infections (BSIs) due to metallo-β-lactamase (MBL)–producing Enterobacterales treated either with CAZ-AVI plus ATM or other active antibiotics (OAAs). Methods This was a prospective observational study including patients admitted to 3 hospitals in Italy and Greece. The primary outcome measure was 30-day all-cause mortality. Secondary outcomes were clinical failure at day 14 and length of stay after BSI diagnosis. Cox regression analysis including a propensity score (PS) for receiving CAZ-AVI + ATM was performed to evaluate primary and secondary outcomes. A PS-based matched analysis was also performed. Results We enrolled 102 patients with BSI; 82 had infections caused by NDM-producing (79 Klebsiella pneumoniae and 3 Escherichia coli) and 20 by VIM-producing (14 K. pneumoniae, 5 Enterobacter species, 1 Morganella morganii) strains. The 30-day mortality rate was 19.2% in the CAZ-AVI + ATM group vs 44% in the OAA group (P = .007). The PS-adjusted analysis showed that the use of CAZ-AVI + ATM was associated with lower 30-day mortality (hazard ratio [HR], 0.37 [95% confidence interval {CI}, .13–.74]; P = .01), lower clinical failure at day 14 (HR, 0.30 [95% CI, .14–.65]; P = .002), and shorter length of stay (subdistributional HR, 0.49 [95% CI, .30–.82]; P = .007). The PS-matched analysis confirmed these findings. Conclusions The CAZ-AVI + ATM combination offers a therapeutic advantage compared to OAAs for patients with BSI due to MBL-producing Enterobacterales. Further studies are warranted.
科研通智能强力驱动
Strongly Powered by AbleSci AI